[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 2 sources · 10 days · First seen · Last updated

L3Harris Technologies financial and strategic developments

Overview

L3Harris Technologies reported strong second-quarter 2026 financial results, including $5.9 billion in revenue and a record $42 billion order backlog. Despite these earnings and raised full-year guidance, the company's stock fell 11% following the announcement that it would postpone the initial public offering and spinoff of its missile business until next year due to market conditions. During this period, the Royal Bank of Canada reduced its stake in the company.

Entities

Royal Bank of Canada · Nurix Therapeutics, Inc. · NewEdge Advisors LLC · L3Harris Technologies · L3Harris Technologies Inc

Timeline

  1. 6 days ago

    [BUSINESS] 2 sources
    Institutional investors increase stakes in L3Harris and Nurix Therapeutics

    Institutional investors have increased stakes in L3Harris Technologies and Nurix Therapeutics, according to recent SEC filings and analyst reports.

  2. 15 days ago

    [BUSINESS] 10 sources
    L3Harris Technologies Shares Drop 11% After Strong Q2 Results and Missile IPO Delay

    L3Harris posted strong Q2 2026 results—$5.9B revenue, record $42B backlog—but shares fell 11% after delaying its missile unit IPO, and RBC trimmed its stake.

Sources

mommygearest.com · stocknews.com